Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
- Status
- RECRUITING
- Phase
- PHASE2
Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
- Status
- RECRUITING
- Phase
- NA
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE3